Addex Shares Are Trading Lower After the Company Announced the Phase 2 ADX71149 Epilepsy Study Did Not Achieve Statistical Significance for the Primary Endpoint of Time for Patients to Reach Baseline Seizure Count When ADX71149 Was Added to Standard of Care
Addex 宣佈第 2 階段 ADX71149 癲癇研究在將 ADX71149 加入護理標準時患者達到基線發作次數的主要終點未達到統計學意義，此後 Addex 股價走低